Mcap $6.7 M / Big EFFECTIVE Cancer Drug in P3 (MKT Size ~$500M+) =20+BAGGER

RAC is definitely one of the cheapest Cancer play out there with a laughable valuation of $6.7 Million . The Cancer Drug (bisantrene) is so effective it was approved in France and it works in various cancers so there is a big chance that Phase 3 trial will be a success (more infos click link below) . Alone the upfront payments from potential partner for the drug coule be multiple higher than the entire valuation of RAC . Conclusion : SUPER STRONG BUY !!!!

ASX Biotech Eyes International Distribution of Overlooked Cancer Drug

https://www.nextbiotech.com.au/asx-biotech-eyes-international-distribution-fda-approved-cancer-drug/

Yet during its testing against other cancers, it showed remarkable activity in AML. In fact, the Phase 2 results were so impressive that the drug was actually approved in one country for treating AML. The problem was that AML was a relatively small disease in the cancer world, with less than 20,000 new cases each year in the US. In contrast, breast cancer is the most lucrative cancer market for pharmaceutical companies, with around 330,000 new cases per year. AML was seen as an ‘orphan’ market with low sales potential and just not worthwhile for big pharma.

So the drug disappeared for 25 years before it was found and reclaimed by this biotech company with the mission to bring the ‘forgotten’ drug to the market for AML. Since listing in 2016, this micro-cap has successfully manufactured the drug and is planning to start a final study next year in order to get FDA approval for AML.

Back in July, it added an unexpected and valuable milestone when its drug received a ‘Rare Paediatric Disease’ (RPD) designation from the FDA. This qualifies the drug to receive a valuable ‘Priority Review Voucher’ (PRV) with the FDA and there’s every reason to expect it to receive this designation. The PRV is essentially a ticket to a fast-track (6-month) FDA review that can be sold to other companies and there is an active secondary market for PRVs, with PRVs selling in the range of ~A$150-$175 million.

Another key avenue for this company to make money in the short term is a Named Patient Program (NPP) outside the US, with a focus on Europe. NPPs are designed to provide physicians with access to unapproved medicines for patients with life-threatening diseases, like AML. In some countries it’s possible to generate revenues from these NPPs.

Midway through the year, the company presented a case study at the International Conference on Leukaemia and Hematologic Oncology in Paris, on two girls with r/r AML who were successfully treated with the drug in 1984 and 1991. The two girls are still alive today because of the drug.

Given its unique safety profile, the drug could be a strong contender for use in treating kids with AML, and this case study (while admittedly being a small sample) is more evidence that there could be real potential here.